Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
Takeda filed a 6-K on Jan 30, 2025, standard foreign issuer report.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on January 30, 2025, reporting as a foreign private issuer. The filing indicates Takeda is submitting its report under the 1934 Securities Exchange Act, with its principal executive offices located in Tokyo, Japan.
Why It Matters
This filing is a routine report for foreign private issuers, providing updates to the SEC and investors on the company's activities.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain material new financial information or strategic changes.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
- 0001395064-25-000002 (accession_number) — Unique identifier for the filing
- 001-38757 (sec_file_number) — SEC file number for Takeda
- January 2025 (date) — Reporting period for the 6-K
- 20549 (zip_code) — SEC Washington D.C. zip code
FAQ
What type of filing is this 6-K for Takeda Pharmaceutical?
This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this 6-K filed?
The filing was made on January 30, 2025.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Does Takeda file its annual reports under Form 20-F or 40-F?
Takeda indicates it files annual reports under Form 20-F.
What is the SEC Commission File Number for Takeda?
Takeda's SEC Commission File Number is 001-38757.
Filing Stats: 4,596 words · 18 min read · ~15 pages · Grade level 7.2 · Accepted 2025-01-30 06:23:40
Filing Documents
- form6k-1_013025.htm (6-K) — 811KB
- exhibit991_013025.htm (EX-99.1) — 781KB
- logo.jpg (GRAPHIC) — 8KB
- 0001395064-25-000002.txt ( ) — 1604KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date January 30, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Earnings Report ( Kessan Tanshin ) for the Nine-month Period Ended December 31, 2024 (IFRS, Consolidated) January 30, 2025 Takeda Pharmaceutical Company Limited Stock exchange listings Tokyo, Nagoya, Sapporo, Fukuoka TSE Code 4502 URL httpswww.takeda.com Representative Christophe Weber, President CEO Contact Christopher O'Reilly Telephone +81-3-3278-2306 Email takeda.ir.contacttakeda.com Global Head of IR, Global Finance Scheduled date of dividend payment commencement - Supplementary materials for the financial statements Yes Presentation to explain the financial statements Yes (Million JPY, rounded to the nearest million) 1. Consolidated Financial Results for the Nine-month Period Ended December 31, 2024 (April 1 to December 31, 2024) (1) Consolidated Operating Results (year to date) (Percentage figures represent changes over the same period of the previous year) Revenue Operating profit Profit before tax Net profit for the period (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) Nine-month Period Ended December 31, 2024 3,528,152 9.8 417,518 86.3 282,383 181.5 211,241 43.5 Nine-month Period Ended December 31, 2023 3,212,893 4.6 224,144 (44.2) 100,313 (69.3) 147,191 (48.5) Net profit attributable to income for the period Basic earnings per share Diluted earnings per share (Million JPY) (%) (Million JPY) (%) (JPY) (JPY) Nine-month Period Ended December 31, 2024 211,083 43.5 395,293 (36.8) 133.71 131.69 Nine-month Period Ended December 31, 2023 147,085 (48.6) 625,154 (16.7) 94.10 93.17 Core Operating Profit Core EPS (B